The Drug Eluting Stents Center

Filter Your Results

 

News

 

IMPERIAL 12-Month Full Cohort and Long Lesion Sub-Study Results

William A. Gray, MD; Additional commentary by Prof. Stefan Müller-Hülsbeck, MD, EBIR, FCIRSE, FICA, FSIR

January 2019—Sustained drug-release in the SFA drives superior results.

FDA Issues Letter on Potential Increased Mortality With Paclitaxel-Coated Devices in SFA

January 17, 2019 -- On its website, the FDA posted an advisory to peripheral interventionalists and vascular medicine physicians to inform them that the agency is evaluating r…

VIVA Physicians' Vascular Leaders Forum on Drug-Eluting Devices in PAD Scheduled

December 19, 2018 -- VIVA Physicians announced details for a special session of its Vascular Leaders Forum. The goal of the forum is to analyze a recent meta-analysis that ass…

VIVA Physicians to Hold Forum on Drug Elution in Peripheral Artery Disease

December 14, 2018 -- With the recent concerns centered around drug-eluting devices and peripheral arterial disease, VIVA Physicians, a 501(c)3 not-for-profit organization dedi…

Recruitment in BASIL-3 and SWEDEPAD Trials Paused After Report of 5-Year Mortality Risk With DCB/DES in SFA

December 13, 2018 -- Recruitment has been paused in the BASIL-3 clinical trial, according to an announcement from the Birmingham Clinical Trials Unit (BCTU) at the University …

Meta-Analysis Observes Increased Mortality Trend in Trials of Paclitaxel‐Coated SFA Devices, But No Definitive Cause

December 6, 2018 -- A systematic review and meta‐analysis of randomized controlled trials (RCTs) evaluating paclitaxel‐coated balloons and stents in the femoral and/or pop…

Combining a Drug-Coated Balloon and a Bare-Metal Stent: The REsponse Adapted Combination Therapy (REACT) Strategy

Koen Deloose, MD, and B. Patrice Mwipatayi, MD, MMed, MClinEd, FCS, FRACS

September 2018—Allowing vessel response to guide appropriate treatment for SFA disease.

Assessing the Economic Impact of Peripheral Interventions

Yann Gouëffic, MD, PhD; and Valéry-Pierre Riche

September 2018—The difficulties in weighing cost-effectiveness in treatment algorithms remain.

 

advertisement

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.